Investigation and Analysis of Medication Information on Pregnant Women in 166 Drug Instructions of An-ti-diabetic Drugs
10.6039/j.issn.1001-0408.2017.16.39
- VernacularTitle:166份抗糖尿病药品说明书中妊娠妇女用药信息标注情况调查分析
- Author:
Na FENG
- Keywords:
Drug instruction;
Anti-diabetic drug;
Pregnant women
- From:
China Pharmacy
2017;28(16):2301-2304
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To provide reference for specified labeling of medication information on pregnant women in drug in-structions of anti-diabetic drugs. METHODS:All of drug instructions of anti-diabetic drugs in DXY Drugs Information were collect-ed, the medication information labeling on pregnant women was analyzed. RESULTS:Among 166 drug instructions, 147 (88.55%)had listed the item ofdrug use for pregnant and lactating womenalone,and labeled with the drug information on preg-nant women;14(8.43%)had listed the item too,but labeled with no or limited clinical data,and whether pregnant women could use or not was not suggested;5(3.01%)didn't have the item. About without guidance of drug use,there were 3(1.81%)drug in-structions missed guidance,and 14(8.43%)with no or limited clinical data. About with guidance of drug use,49(29.52%)were labeled with forbidden for pregnant women;40(24.1%)were labeled with can't/not suitable/should not be used for pregnant wom-en;49 (29.52%) were labeled with cautious/not recommend/weighed the pros and cons/benefits greater than the risk/consulted a doctor for pregnant women;and 11(6.63%)were labeled with being safe/being not restricted for pregnant women. In the 166 drug instructions,26,which were from foreign pharmaceutical companies,had listed the item ofdrug use for pregnant and lactating womenalone,as well as labeled the guidance of drug use for pregnant women. CONCLUSIONS:The labeling of domestic drug instructions shows inadequate drug information on pregnant women,non-uniform guidance statements,lag of update and other prob-lems,which should be attached to great importance by drug supervision and management departments,as well as pharmaceutical production enterprises.
